This page contains a Flash digital edition of a book.
Meeting the needs


● Step 4 Record your findings and implement them


● Step 5 Review your assessment and update if necessary


Following the above template enables the assessor to identify who could be harmed, but more importantly, encourages them to explore possible solutions, and to propose what processes or products are available to reduce or eliminate the risks identified in all areas of care.


Products available to reduce/ eliminate risk


Introducing a closed system solution CareFusion is committed to lowering the cost of healthcare, while improving patient safety, this commitment also includes protecting healthcare professionals in all work areas. CareFusion offers a safe, cost-effective, easy-to-use closed system to help protect healthcare workers anytime they prepare, transport, administer or dispose of hazardous drugs.


Safer Our Texium® closed male luer is based on


a simple luer lock principle, allowing free flow of the drug when connected, and automatically closing when disconnected. Together, the Texium® and SmartSite®


closed male luer needle-free valve


products partner to form a closed system, providing leak-free connections and disconnections that help to reduce surface contamination and the risk of exposure. When connected, the fluid path opens. This path automatically closes upon disconnection. The patented no-drip technology of the Texium®


closed male


luer creates a vacuum mechanism when closing to ensure a drip-free, leak-free disconnection. SmartSite®


partners with Texium®


vented vial access device closed male luer


for closed system access to drug vials. Simpler


The luer lock connection of the Texium® closed male luer to a SmartSite®


needle-


free valve port helps you quickly and easily to achieve a closed system, without adding cumbersome steps to your clinical process. The Texium®


closed male luer


has an automatic safety lock that prevents accidental discharges from the syringe.


Administration 10


The CareFusion Multi-way Quattro system allows the connection of up to four secondary infusions and delivery of the drug without any need to disconnect the


www.hospitalpharmacyeurope.com


sets. The rigid body reduces risk of kinking, ensuring the drug is promptly delivered to the patient. The back check valve in the secondary set reduces the back track of fluid during the infusion and it is safely connected to the SmartSite® needle-free port.


When this system works in combination with the CareFusion infusion pumps, which are equipped with the Guardrails®


Suite, it can further help


to reduce harmful IV medication errors. Recent studies have proven that the CareFusion system helps to reduce surface contamination and waste of drugs during withdrawals from vials, maintaining drug stability and sterility during use. 12–14 CareFusion provides products that are safer for patients and healthcare professionals during reconstitution, preparation and administration. ●


References 1. NIOSH report NIOSH Alert Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings 2004 Publication No 2004–165.


2. Minoia C et al. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Rapid Commun Mass Spectrom 1998; 12: 1485–93.


3. Connor TH et al. Surface contamination with antineoplastic agents in six cancer treatment centers in the United States and Canada. Am J Health-Syst Pharm 1999; 56: 1427–32.


4. Pethran A et al. Uptake of antineoplastic agents in


pharmacy and hospital personnel. Part 1: monitoring of urinary concentrations. Int Arch Occup Environ Health 2003;76(1):5–10.


5. Valanis B et al. Staff members’ compliance with their facility’s antineoplastic drug handling policy. Onc Nurs Forum 1991; 18(3):571–6.


6. Valanis B et al. Antineoplastic drug handling protection after OSHA guidelines: comparison by profession, handling activity, and work site. J Occup Med 1992; 34:149–55.


7. Mahon SM et al. Safe handling practices of cytotoxic drugs: the results of a chapter survey. Oncol Nurs Forum 1994; 21(7):1157–65.


8. Nieweg RMB et al. Safe handling of antineoplastic drugs. Cancer Nurs 1994; 17:501–11.


9. Ensslin AS et al. Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med 1994; 51:229–33.


10. Ensslin AS et al. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: urinary excretion and cytogenetics studies. Int Arch Occup Environ Health 1997; 70:205–8.


11. Wick C et al. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health-Syst Pharm. 2003; 60:2314–20.


12. Fazio M et al. Closed-loop delivery systems for the preparation and administration of anti-cancer drugs. 2008 XXIV National Congress SIFO.


13. Dreassi E et al. Analysing the interaction between cytotoxic chemotherapy drugs and medical devices used for preparation and administration. Hospital Pharm Eur 2011;61:65-66.


14. Ribeiro-Crespel V. Safe preparation of methotrexate syringe outside a centralised cytotoxic preparation unit. Hospital Pharm Eur 2009;46:63-64.


Document approved number: 0000MS05502


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28